
Free Daily Podcast Summary
by Michael Fernando and Josh Hurwitz
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.
The most recent episodes — sign up to get AI-powered summaries of each one.
This episode is the ASCO 2026 Plenary Episode. This week, all of the pivotal, game-changing, life-changing trials are discussed here. Some describe the plenary session as practice-changing, and we will always agree that better treatments with significant improvements in life expectancy and quality of life need their time in the spotlight.Today, five trials are discussed, including SARC041, a liposarcoma study utilising the CDK 4/6 inhibigtor abemacicilib. Our second study is HARMONI-6, investigating whether ivonescimab plus chemotherapy is effective in patients with advanced squamous non-small cell lung cancer. Our third, almost like something written for an opera (LIBRETTO0-432), a lung cancer trial looking at selpercatinib in those with RET fusion early-stage NSCLCa. PROTEUS emerges as our fourth trial, rising from the depths of the ocean to evaluate apalutamide in the perioperative prostate cancer space.Finally, and most importantly in our opinion, is RASolute302, the pancreatic cancer trial, showing that even the most difficult mutation is now treatable. An incredible story of an exceptionally difficult cancer to treat, Daraxonrasib is the star of this year's ASCO.Studies Discussed in this EpisodeSARC041HARMONI-6LIBRETTO0-432PROTEUSRASolute302For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
This week, Josh and Michael's ASCO 2026 coverage looks at "Agents of the Future", trials of intrigue, promise and potential beyond its status. This episode also sheds light on more orphan status cancers like head and neck cancer, basket cohort studies, resistant EGFR lung cancer, metastatic colorectal cancer and hepatocellular carcinoma.One more episode left of this arc - The Plenary! Stay tuned.Studies Discussed in this EpisodeOrigAMI-4 WU-KONG28A Phase 1/2 Study of JK06, a 5T4-Targeted Antibody Drug Conjugate (ADC), In Patients with Unresectable Locally Advanced or Metastatic CancerESANOAROSETTA Lung-02Ivonescimab + FOLFOXHERIZON-CRC01CIRCULATEEMERALD-3BLUESTARGLP-1 agonist in breast cancer (Palleschi et al)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
ASCO 2026 is done, and Michael and Josh have created a marathon episode for you all. This week we cover "Agents of the Present", where we summarise all the important trials with updates, overall survival and progression-free survival data that could influence your practice.They cover immunotherapy, lifestyle interventions, pan-PI3K inhibitors, rare cancers (such as uveal melanoma), and antibody drug conjugates, to name a few. All the cancer types are covered, including genitourinary, gynaecological cancers, breast, colorectal, lung and lifestyle interventions!Two more episodes to come!Studies Discussed in this EpisodeEV-302 Extended Follow-UpROSELLA (Ovarian Cancer)RAMPART (Adjuvant RCC)VIKTORIA-1 (HR +ve Breast Cancer)OptimUMOPTIMA (Breast Cancer)Anbenitimab and Chemotherapy (HER2 +ve Breast Cancer)TALAPRO-3 (Prostate Cancer)GLP-1 in HR +ve Breast CancerLifestyle Interventions in HR +ve Breast CancerFor more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
This week, we take a quick trip to Stockholm, Sweden, where ESTRO (European Society for Radiotherapy and Oncology) took place several weeks ago. A/Prof Steven David digs deep into the latest updates in the breast cancer radiation space, including hyperfractionation of treatment, the utilisation of AI for radiation planning (Archery Trial), and the DBCG RT Natural Trial, which examined whether omitting partial breast irradiation (PBI) after breast-conserving surgery was safe in those over 60 (spoiler: you should still give PBI).For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
This episode tells the story of how one man, Jake Messier, is challenging the stigma surrounding male metastatic breast cancer, a disease affecting 1% of all breast cancer patients. It's an important reminder that not all cancers are funded and researched equally, and that behind every statistic is a person trying to live a normal life.Jake has used his lifelong PR skills to turn what is a diagnosis unlike any other into a conversation about equity, resilience and a deep societal stigma. This conversation should also serve as a reminder of how patients perceive the healthcare system and that communication is key when treating patients, many of whom are vulnerable.A huge thank you to Jake for coming on the show. If you want more information, see Jake's website: https://www.theguywithstage4breastcancer.com/For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
This week, we take a "back to the future" look at the early-stage pancreatic cancer phase, a relatively stagnant area in terms of pivotal trials. The two trials are the ESPAC4 trial, which examines doublet chemotherapy in pancreatic cancer, and Josh does a traditional deep dive into the world of neoadjuvant chemotherapy. He highlights ESPAC-5, PREOPANC-2, and the TAPS consortium, to name a few. A complicated but overall evolving field.Studies discussed in this episode:ESPAC-4FOLFOXIRIPREOPANC-2ESPAC-5TAPS (Trans-Atlantic Pancreatic Surgery (TAPS) Consortium Study)For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Today, we accidentally skipped early pancreatic cancer and jumped straight to advanced pancreatic cancer. It was a sombre episode, with clinicians and advocates screaming for better treatment options for this cancer. While small incremental advances have been made, the holy grail remains elusive.Today our focus is on NAPOLI-3, the use of liposomal irinotecan (NALIRIFOX), and PANOVA-3, where TTFields are used in combination with gemcitabine/abraxane. A good conversation, though the current premise is sad. Hopefully, as time moves on, this conversation will be more optimistic. Studies discussed in this episode:NAPOLI-3PANOVA-3For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
On today's episode, Josh and Michael "advance" in their ongoing GI journey, as Michael continuously insists on saying, to discuss advanced gastric and GOJ cancer. Historically an orphan disease with very poor prognosis, perhaps the first rays of light are beginning to shine on this difficult-to-treat cancer type. Immunotherapy has been well established as standard of care, but are there any new agents that are emerging in this space? As always, the answer to that question is "yes," and as usual, the agent in question is trastuzumab deruxtecan. Listen on for all the surprising details, even more awful puns, and a strange tangent about the difference between a "good" and "effective" dictator.Studies discussed in this episode:Checkmate 648/649Destiny-Gastric01For more episodes, resources and blog posts, visit www.inquisitiveonc.comPlease find us on Twitter @InquisitiveOnc!If you want us to look at a specific trial or subject, email us at inquisitiveonc@gmail.comArt courtesy of Taryn SilverMusic courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.Oncology for the Inquisitive Mind is recorded with the support of education grants from our foundation partners Pfizer and Merck Pharmaceuticals. Our partners have access to the episode at the same time you do and have no editorial control over the content. Hosted on Acast. See acast.com/privacy for more information.
Free AI-powered daily recaps. Key takeaways, quotes, and mentions — in a 5-minute read.
Get Free Summaries →Free forever for up to 3 podcasts. No credit card required.
Listeners also like.

Out of the Gray (Gy) - Standard Imaging
Conversations with experts in radiation oncology exploring advancements in technology, research, and clinical practice.

The Curbsiders Internal Medicine Podcast
Expert-led internal medicine discussions with clinical insights and humor for primary care and hospital medicine providers.

Jon Holmes Says the C-Word
A man discusses his cancer experience with guests, sharing honest and often humorous stories about diagnosis and treatment.

The Peter Attia Drive
Conversations with experts on health, longevity, performance, and critical thinking led by physician Peter Attia.

The Dr. Gabrielle Lyon Show
Discusses health, longevity, and mental resilience through science-based conversations with medical and wellness experts.

Inquiring Minds
Explores the intersection of science and society through critical thinking and in-depth analysis.

Plenary Session
Discusses medicine, oncology, and health policy with expert guests and critical analysis.

Huberman Lab
Explores neuroscience and science-based tools for understanding and improving brain function, behavior, and health.

Red Pill Your Healthcast
Two healthcare providers discuss overlooked health issues and empower listeners to make informed decisions for their families.

Psychiatry & Psychotherapy Podcast
Explores psychiatry and psychotherapy through interviews with experts, trainees, and individuals sharing lived mental health experiences.

The Bob & Cancer Show
A couple and their friend share their honest experiences navigating a gastric cancer diagnosis, treatment, and the emotional challenges that follow.

Health Discovered
Doctors explore surprising stories to uncover insights about health and well-being.
Cancer is a fascinating but rapidly evolving discipline - it's a full-time job just keeping up to date. In this podcast, Dr Michael Fernando and Dr Joshua Hurwitz explore the latest trials, research, and practice-changing updates, as well as regular interviews with renowned oncology specialists. Ideal for those starting their training journey, established specialists and anyone interested in medical science, oncological practice, or terrible jokes. Preferably all three.
AI-powered recaps with compact key takeaways, quotes, and insights.
Get key takeaways from Oncology for the Inquisitive Mind in a 5-minute read.
Stay current on your favorite podcasts without falling behind.
It's a free AI-powered email that summarizes new episodes of Oncology for the Inquisitive Mind as soon as they're published. You get the key takeaways, notable quotes, and links & mentions — all in a quick read.
When a new episode drops, our AI transcribes and analyzes it, then generates a personalized summary tailored to your interests and profession. It's delivered to your inbox every morning.
No. Podzilla is an independent service that summarizes publicly available podcast content. We're not affiliated with or endorsed by Michael Fernando and Josh Hurwitz.
Absolutely! The free plan covers up to 3 podcasts. Upgrade to Pro for 15, or Premium for 50. Browse our full catalog at /podcasts.
Oncology for the Inquisitive Mind publishes weekly. Our AI generates a summary within hours of each new episode.
Oncology for the Inquisitive Mind covers topics including Science, Education, Medicine, Fitness, Health & Fitness, Life Sciences. Our AI identifies the specific themes in each episode and highlights what matters most to you.
Free forever for up to 3 podcasts. No credit card required.
Free forever for up to 3 podcasts. No credit card required.